Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

Can big data give medical affairs an edge in strategic planning?

Teams can better identify, and engage with, KOLs while also measuring their endeavours

What will the NHS’s Capped Expenditure Process (CEP) mean for pharma?

Paul Midgley, Director of NHS Insight at Wilmington Healthcare, explains how pharma should tailor its approach

Wilmington Healthcare

Roche Basel Switzerland

Roche’s Actemra/RoActemra receives new European approval

EU regulators also pass the Swiss pharma firm’s Gazyvaro

- PMLiVE

Versartis crashes as VELOCITY trial veers off track

The US biotech's somavaratan proved inferior to Pfzier’s Genotropin

- PMLiVE

FDA wants more data on J&J’s arthritis drug Plivensia

Requests further evidence on the drug’s safety profile after patient deaths link

- PMLiVE

Prof Sir Mike Richards joins Incisive Health as senior counsel

He recently stepped down as chief inspector of hospitals

AI’s potential in the pharma life cycle

At a time that the future of life sciences is being hotly debated, the opportunity for the industry to refine and expand its role is an important one to take...

- PMLiVE

Dr Paula Salmikangas joins NDA Group

Moves to the regulatory affairs consultancy from the Finnish Medicines Agency

- PMLiVE

And breathe…

…or, why there is no ‘fast track’  to communications excellence

- PMLiVE

Humanisation

The key to delivering communications excellence

- PMLiVE

Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio

Germany and the UK will be the first to receive the skin cancer treatment

- PMLiVE

Intercept hit hard as FDA issues Ocaliva safety notice

The PBC treatment has been linked to 19 deaths and 11 cases of liver damage

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links